Results 171 to 180 of about 196,414 (282)

Targeting the role played by microbiota and adaptive immunity within autoimmune disease complexity. [PDF]

Front Immunol
Bredberg A, Nermo KR, Henriksson G.
europepmc   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Pregnancy and autoimmune disease: diseases of the nervous system, connective tissue, and the bowel

Deutsches Ärzteblatt international, 2022
Merz, Waltraut Maria, Fischer-Betz, Rebecca, Hellwig, Kerstin, Lamprecht, Georg, Gembruch, Ulrich   +4 more
openaire   +1 more source

The Value of Oligoclonal Bands in Multiple Sclerosis Compared to Other Neurological Disorders: A Retrospective Data Analysis From an Austrian Tertiary Center. [PDF]

Eur J Neurol
Monschein T, Scheicher B, Ponleitner M, Krajnc N, Föttinger F, Zrzavy T, Rommer P, Kornek B, Bsteh G, Perkmann T, Berger T, Leutmezer F.   +11 more
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

New-onset refractory status epilepticus associated with Sjögren's disease. [PDF]

BMJ Neurol Open
Lim GZ, Kwok JKG, Fan Z, Koh NWC, Lee JS, Yeo T.   +5 more
europepmc   +1 more source

The Immunobiology of Multiple Sclerosis: An Autoimmune Disease of the Central Nervous System

Neurobiology of Disease, 1999
Paul Conlon, Jorge R. Oksenberg, Jingwu Zhang, Lawrence Steinman   +3 more
openaire   +3 more sources

Predicting epilepsy after new onset refractory status epilepticus due to autoimmune encephalitis: The DAME score

Epilepsia, EarlyView.
Abstract Objective This study aimed to identify risk factors and develop a predictive scoring system for autoimmune‐associated epilepsy in subjects with autoimmune encephalitis presenting with new onset refractory status epilepticus (NORSE). Methods This retrospective, multicenter, cohort study included subjects who presented with NORSE at the onset of
Simona Lattanzi, Sara Matricardi, Alberto Vogrig, Giada Pauletto, Margherita Nosadini, Stefano Sartori, Federico Massa, Luana Benedetti, Stefano Meletti, Francesca Bisulli, Elena Freri, Francesca Felicia Operto, Silvia Bozzetti, Sara Mariotto, Simone Beretta, Eleonora Rosati, Elisabetta Cesaroni, Carla Marini, Tiziana Granata, Flavio Villani, Immune Epilepsies Study Group of the Italian League Against Epilepsy, Ruggero Bernabei, Stefania Maria Bova, Silva Cappanera, Luigi Caputi, Edward Cesnik, Francesco Deleo, Lidia Di Vito, Giuseppe D’Orsi, Giovanni Falcicchio, Elisa Fallica, Edoardo Ferlazzo, Lucia Fusco, Matteo Gastaldi, Giada Giovannini, Angela La Neve, Claudio Liguori, Pietro Mattioli, Lorenzo Muccioli, Carlotta Mutti, Angelo Pascarella, Elena Pasini, Daniela Passarelli, Francesca Ragona, Romana Rizzi, Elena Tartara, Valentina Tontini, Alberto Verrotti, Federica Zibordi, Lucia Zinno, Antonio Zito   +50 more
wiley   +1 more source

Anti-NMDA receptor encephalitis unmasking Sjögren's disease: a case report and literature review. [PDF]

Front Immunol
Dimitrov G, Deneva V, Mantarova-Valkova S.   +2 more
europepmc   +1 more source

Freedon study: Real‐life outcomes of cenobamate in different lines of treatment

Epilepsia, EarlyView.
Abstract Objectives Cenobamate is an antiseizure medication (ASM) with proven effectiveness in individuals with highly refractory epilepsy. This study investigated the effectiveness and tolerability of cenobamate in different treatment lines and a less refractory setting. Methods This was a multicenter, retrospective, observational study.
Vicente Villanueva, José María Serratosa, Alejandro Fernández‐Cabrera, Manuel Toledo, Beatriz González‐Giráldez, José C. Estevez, Juan Jesús Rodríguez Uranga, Maria Machio Castelló, Maria Dolores Castro‐Vilanova, Juan José Poza, Xiana Rodríguez‐Osorio, Kevin G. Hampel, Elena Fonseca, Francisco Javier López‐González, Mercedes Garcés, Laura Abraira, Jordi Ciurans, Daniel Campos‐Fernández, Estevo Santamarina, Juan María Sanchez‐Caro, Lucas Iacampo, Julia Renau, Miguel Ángel García‐Quesada, Carla Anciones, María Isabel Chamorro, Iratxe Maestro, Pablo Cabezudo, Raquel Calle, Jesús Macarron, Beatriz Cabezas, María Carrasco, María López, Marta Marín, Rosa Querol, Belén Baena, Vanessa García‐Morales, Samuel López‐Maza, Álvaro Juiz, Blanca Mercedes‐Alvarez, Carla Amarante, Ana del Villar, Ascensión Castillo, Marta Rubio‐Roy, Javier Martinez‐Poles, Asier Gómez‐Ibáñez, Beatriz Parejo‐Carbonell, Anabelén Martínez Garcia, Ignacio Carrera, Pablo Iriarte, Fátima Romero‐Aguilera, on behalf of the Pharmacological Therapy Working group of the Spanish Epilepsy Society and Freedon Group   +50 more
wiley   +1 more source